Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 10/20 | 0.79 |
| ▸ | KDR | P35968 | 8/20 | 0.79 |
| ▸ | BRAF | P15056 | 6/20 | 0.79 |
| ▸ | RET | P07949 | 4/20 | 0.79 |
| ▸ | ABL1 | P00519 | 4/20 | 0.79 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.79 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.79 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.79 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.79 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.79 |
| ▸ | HTR1A | P08908 | 2/20 | 0.79 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.79 |
| ▸ | KIT | P10721 | 2/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.79 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.79 |
| ▸ | FLT1 | P17948 | 2/20 | 0.79 |
| ▸ | MAOA | P21397 | 2/20 | 0.79 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14751419 | 0.94 | KDR (0.70) | RAF1KDRBRAFRETABL1 | |
| SCHEMBL10105558 | 0.92 | KDR (0.71) | RAF1KDRBRAFRETABL1 | |
| SCHEMBL10105571 | 0.92 | RAF1 (0.66) | RAF1KDRBRAFRETABL1 | |
| SCHEMBL12283302 | 0.91 | KDR (0.66) | RAF1KDRBRAFRETABL1 | |
| SCHEMBL14751478 | 0.91 | KDR (0.65) | RAF1KDRBRAFRETABL1 | |
| SCHEMBL10105574 | 0.90 | RAF1 (0.64) | RAF1KDRBRAFRETABL1 | |
| SCHEMBL14751476 | 0.90 | KDR (0.64) | RAF1KDRBRAFRETABL1 | |
| SCHEMBL10324287 | 0.89 | RAF1 (0.75) | RAF1KDRBRAFRETABL1 | |
| SCHEMBL10105567 | 0.89 | RAF1 (0.68) | RAF1KDRBRAFRETABL1 | |
| SCHEMBL19888727 | 0.89 | RAF1 (0.75) | RAF1KDRBRAFRETABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170268065-A1 | ERK1 and ERK2 Mutations That Confer Resistance to MAPK Pathway Inhibitors | DANA-FARBER CANCER INSTITUTE, INC. | 2017-09-21 | — | — | US | disclosed |
| US-9518020-B2 | Process for Regorafenib | HETERO RESEARCH FOUNDATION (IN) | 2016-12-13 | — | — | US | disclosed |
| US-20160251313-A1 | PROCESS FOR REGORAFENIB | HETERO RESEARCH FOUNDATION (IN) | 2016-09-01 | — | — | US | disclosed |
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS GROUP, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2558448-B1 | PROCESS FOR THE PREPARATION OF 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)-PHENYL]AMINO}CARBONYL)AMINO]-3-FLUOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE, ITS SALTS AND MONOHYDRATE | BAYER HEALTHCARE LLC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-20120077851-A1 | Urea Derivatives as Kinase Inhibitors | MEDOLUTION LIMITED (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | KRAS, NRAS, TP53 | RAF1 11/4885KDR 953/4885BRAF 5/4885 |
| US-20160251313-A1 | PROCESS FOR REGORAFENIB | KDR, PDGFRA, RET | RAF1 665/4885KDR 1/4885BRAF 75/4885 |
| US-20120077851-A1 | Urea Derivatives as Kinase Inhibitors | MAP3K20, CDK20, MAP3K10 | RAF1 15/4885KDR 1768/4885BRAF 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.